Immunotherapy for Head and Neck Cancer in the Era of Exponentially Increasing Health Care Expenditure

The FDA‐approved immune checkpoint inhibitors, nivolumab and pembrolizumab, are the most recent biological therapies in the therapeutic armamentarium for recurrent metastatic head and neck squamous cell carcinomas. This article highlights the tools for analyzing the costeffectiveness of such therapi...

Descripción completa

Detalles Bibliográficos
Autores principales: Santana‐Davila, Rafael, Rodriguez, Cristina P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813756/
https://www.ncbi.nlm.nih.gov/pubmed/29192017
http://dx.doi.org/10.1634/theoncologist.2017-0527
_version_ 1783300230481969152
author Santana‐Davila, Rafael
Rodriguez, Cristina P.
author_facet Santana‐Davila, Rafael
Rodriguez, Cristina P.
author_sort Santana‐Davila, Rafael
collection PubMed
description The FDA‐approved immune checkpoint inhibitors, nivolumab and pembrolizumab, are the most recent biological therapies in the therapeutic armamentarium for recurrent metastatic head and neck squamous cell carcinomas. This article highlights the tools for analyzing the costeffectiveness of such therapies.
format Online
Article
Text
id pubmed-5813756
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher AlphaMed Press
record_format MEDLINE/PubMed
spelling pubmed-58137562018-02-21 Immunotherapy for Head and Neck Cancer in the Era of Exponentially Increasing Health Care Expenditure Santana‐Davila, Rafael Rodriguez, Cristina P. Oncologist Commentaries The FDA‐approved immune checkpoint inhibitors, nivolumab and pembrolizumab, are the most recent biological therapies in the therapeutic armamentarium for recurrent metastatic head and neck squamous cell carcinomas. This article highlights the tools for analyzing the costeffectiveness of such therapies. AlphaMed Press 2017-11-30 2018-02 /pmc/articles/PMC5813756/ /pubmed/29192017 http://dx.doi.org/10.1634/theoncologist.2017-0527 Text en © AlphaMed Press 2017
spellingShingle Commentaries
Santana‐Davila, Rafael
Rodriguez, Cristina P.
Immunotherapy for Head and Neck Cancer in the Era of Exponentially Increasing Health Care Expenditure
title Immunotherapy for Head and Neck Cancer in the Era of Exponentially Increasing Health Care Expenditure
title_full Immunotherapy for Head and Neck Cancer in the Era of Exponentially Increasing Health Care Expenditure
title_fullStr Immunotherapy for Head and Neck Cancer in the Era of Exponentially Increasing Health Care Expenditure
title_full_unstemmed Immunotherapy for Head and Neck Cancer in the Era of Exponentially Increasing Health Care Expenditure
title_short Immunotherapy for Head and Neck Cancer in the Era of Exponentially Increasing Health Care Expenditure
title_sort immunotherapy for head and neck cancer in the era of exponentially increasing health care expenditure
topic Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813756/
https://www.ncbi.nlm.nih.gov/pubmed/29192017
http://dx.doi.org/10.1634/theoncologist.2017-0527
work_keys_str_mv AT santanadavilarafael immunotherapyforheadandneckcancerintheeraofexponentiallyincreasinghealthcareexpenditure
AT rodriguezcristinap immunotherapyforheadandneckcancerintheeraofexponentiallyincreasinghealthcareexpenditure

Ejemplares similares